B1 Vertaisarvioitu muu artikkeli (esim. pääkirjoitus, letter, comment) tieteellisessä lehdessä
Physician global assessment in rheumatoid arthritis—is there any logic?
Tekijät: Jäppinen, Katriina; Muilu, Paula; Autio, Reija; Kuusalo, Laura; Sihvonen, Susanna; Sokka-Isler, Tuulikki; Rantalaiho, Vappu
Kustantaja: Oxford University Press (OUP)
Julkaisuvuosi: 2025
Lehti: Rheumatology Advances in Practice
Artikkelin numero: rkaf139
Vuosikerta: 9
eISSN: 2514-1775
DOI: https://doi.org/10.1093/rap/rkaf139
Julkaisun avoimuus kirjaamishetkellä: Avoimesti saatavilla
Julkaisukanavan avoimuus : Kokonaan avoin julkaisukanava
Verkko-osoite: https://doi.org/10.1093/rap/rkaf139
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/505903441
Ladattava julkaisu This is an electronic reprint of the original article. |  |
Julkaisussa olevat rahoitustiedot:
Vappu Rantalaiho received a personal grant for the expenses of the research group from the Competitive State Research Financing of the Expert Responsibility Area of Kanta-Häme Central Hospital and of the Wellbeing Services County of Pirkanmaa.
P.M. has received travel reimbursement from Abbvie, Orion Pharma and Boehringer Ingelheim. L.K. has received a personal grant from State Research Funding of Wellbeing Services County of South-West Finland, has a relationship including consulting and advisory with Galapagos, a relationship including consulting or advisory and speaking and lecture fees with Jannsen-Cilag, Pfizer and UCB, and has received speaking and lecture fees from Abbvie, Boehringer Ingelheim, Lilly and Medac. S.S. has received travel reimbursement from Pfizer, Novartis, and Medac. TS-I has received speaking and lecture fees from Abbvie, Lipum, Pfizer, Nordic Medicine and UCB, and has received grants from Amgen and Nordic Pharma. V.R. has received funding grants from Competitive State Research Financing of the Expert Responsibility Area of Kanta-Häme Central Hospital and of the Wellbeing Services County of Pirkanmaa, and Wilhelm and Else Stockmanns Foundation, and reports speaking and lecture fees from Novartis, Viatris, Abbvie, BMS, Johnson & Johnson, Medac and is a board member of Lilly. The remaining authors have declared no conflicts of interest.
